Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Padcev Sales Exceed Expectations As Seattle Genetics Pursues Earlier Indications

May 01 2020

• By Mandy Jackson

Hitting bigger business target — Analysts raised their Padcev forecasts based on Q1 sales

Related Content

Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch

Apr 18 2020

Lilly, Galapagos Put Some Trials On Hold Due To Coronavirus Concerns

Mar 24 2020

Bad For Pharma: Sales Reps And Patients Are Staying Home

Mar 18 2020

Bladder Cancer: Positive Signs For Tecentriq, Seattle Genetics Shines

Sep 30 2019

Astellas, Seattle Genetics Break Ground With US ADC Approval

Dec 19 2019

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

Feb 21 2020

Related Companies

Seagen Inc.

Astellas Pharma, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Additional Topics

Launches Business Strategies Sales & Earnings Companies Commercial Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window